In SPC-treated lung cancer cells, E-cadherin levels were downregulated, whereas N-cadherin and YDJC levels were upregulated (Figure 2), which was followed by increased migration and invasion (Figure 2(d)). The gene discussed is CDH2; the disease is lung carcinoma.